ATOSSA THERAPEUTICS, INC. Logo

ATOSSA THERAPEUTICS, INC.

Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.

ATOS | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
10202 5TH AVENUE NE, 98125 SEATTLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address significant unmet needs in oncology, specifically for breast cancer treatment and prevention. The company's lead program is the development of (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen to target multiple breast cancer indications across the treatment continuum, including metastatic breast cancer, aiming to improve patient outcomes with a potentially more effective and tolerable therapeutic.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ATOSSA THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ATOSSA THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ATOSSA THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea 291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America ABUS

Talk to a Data Expert

Have a question? We'll get back to you promptly.